Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Juleen Gayed"'
Autor:
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 4, Pp 699-714 (2024)
Abstract Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participant
Externí odkaz:
https://doaj.org/article/90c062f7697b4812bbed4dc9541f00d7
Autor:
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin
Publikováno v:
Vaccines, Vol 12, Iss 7, p 734 (2024)
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included health
Externí odkaz:
https://doaj.org/article/4918551c78fb4b61aeeec58f4aba83f5
Autor:
Juleen Gayed, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, Mark Cutler, Todd Belanger, David Cooper, Kenneth Koury, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Alejandra Gurtman, Nicholas Kitchin
Publikováno v:
Vaccines, Vol 12, Iss 2, p 118 (2024)
Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of an ongoing, open-label, phase 2/3 study of monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg d
Externí odkaz:
https://doaj.org/article/37ba4c9bf2d9424caf31c4184fb3a07c
Autor:
Patricia Winokur, Juleen Gayed, David Fitz-Patrick, Stephen J. Thomas, Oyeniyi Diya, Stephen Lockhart, Xia Xu, Ying Zhang, Vishva Bangad, Howard I. Schwartz, Douglas Denham, Jose F. Cardona, Lisa Usdan, John Ginis, Federico J. Mensa, Jing Zou, Xuping Xie, Pei-Yong Shi, Claire Lu, Sandra Buitrago, Ingrid L. Scully, David Cooper, Kenneth Koury, Kathrin U. Jansen, Özlem Türeci, Uğur Şahin, Kena A. Swanson, William C. Gruber, Nicholas Kitchin
Publikováno v:
New England Journal of Medicine. 388:214-227
Autor:
Jorg Taubel, Asif Naseem, Georg Ferber, Satomi Nishimura, John Camm, Satomi Adachi-Akahane, Atsushi Sugiyama, Juleen Gayed, Yuji Kumagai, Yuji Nakamura
Publikováno v:
British Journal of Clinical Pharmacology. 73:455-459
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Although the ICH guidelines state that it is not expected that the results of a ‘thorough QT interval/corrected QT interval (QT/QTc)’ study would be affected by ethnic factors and would consequently be
Autor:
William van’t Hoff, David Erbe, Pierre Cochat, Daniella Magen, Patrick Haslett, Jaap W. Groothoff, Jiandong Lu, Yaacov Frishberg, Pushkal Garg, Georges Deschênes, Akshay Vaishnaw, Sandeep Talamudupula, Ulrike Lorch, Sally-Anne Hulton, Jérôme Harambat, Tracy L. McGregor, John C. Lieske, Dawn S. Milliner, Bahru A. Habtemariam
Publikováno v:
Clinical Journal of the American Society of Nephrology
Clinical Journal of the American Society of Nephrology, American Society of Nephrology, 2021, pp.CJN.14730920. ⟨10.2215/cjn.14730920⟩
Clinical journal of the American Society of Nephrology, 16(7), 1025-1036. American Society of Nephrology
Clin J Am Soc Nephrol
Clinical Journal of the American Society of Nephrology, American Society of Nephrology, 2021, pp.CJN.14730920. ⟨10.2215/cjn.14730920⟩
Clinical journal of the American Society of Nephrology, 16(7), 1025-1036. American Society of Nephrology
Clin J Am Soc Nephrol
International audience; BACKGROUND AND OBJECTIVES: In the rare disease primary hyperoxaluria type 1, overproduction of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1739805a88aa63ffcc6bf79348807932
https://hal.archives-ouvertes.fr/hal-03279682
https://hal.archives-ouvertes.fr/hal-03279682